Neha Mehta-Shah

28PUBLICATIONS
191CO-AUTHORS
Molecular targetsHaematological tumoursPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Aug 25, 2026
Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.

|Apr 22, 2026
Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.

|Feb 18, 2026
Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study.

Jia Ruan, Zhengming Chen, Melissa C Larson

|Feb 09, 2026
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.

Catherine Diefenbach, Opeyemi Jegede, Victoria Wang

|Feb 09, 2026
Multiomic study of cutaneous T-cell lymphoma reveals single-cell clonal evolution in progression and therapy resistance.

Hannah K Dorando, Jared M Andrews, Oam U Khatavkar

|Sep 25, 2025
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.

Carrie Thompson, Marek Trněný, Franck Morschhauser

Pageof 5

Frequent Collaborators

8 joint publications

Nancy L Bartlett

5 joint publications

Marcus P Watkins

5 joint publications

Brad S Kahl

4 joint publications

Pier Luigi Zinzani